Abstract

Objective: To compare trends in the use of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA), between Korea and Australia.
Materials and methods: Using sampled claims databases in Korea and Australia (2010 – 2018), we analyzed the trends in the use of individual targeted DMARDs (biologic and targeted synthetic) for RA in both countries.
Results: The use of targeted DMARDs for the management of RA showed an increase of over 200 and 300% in Australia and Korea, respectively. The tumor necrosis factor inhibitors (TNFis) etanercept and adalimumab were the most commonly prescribed drugs in 2010 in both countries, with non-TNFi use increasing over the study period. The introduction of tofacitinib in 2015 led to 10 and 15% market share uptake in Korea and Australia, respectively.
Conclusion: Trends in the use of targeted DMARDs for RA were similar in Korea and Australia, and the use of non-TNFis, including tofacitinib, increased in both countries.

Author Details

Authors

• So-Hee Park¹
• Ha-Lim Jeon¹
• Seoyoung C. Kim^{2, 3}
• Jodie Hillen⁵
• Svetla Gadzhanova⁵
• Ju-Young Shin^{1, 4}
• Nicole Pratt⁵

Departments

• ¹ School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea,
• ² Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,
• ³ Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA,
• ⁴ Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea, and
• ⁵ Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia

Address


Ju-Young Shin, PhD, Associate Professor

School of Pharmacy, Sungkyunkwan University
2066 Seobu-ro, Jangan-gu, Suwon,
Gyeonggi-do 16419, Republic of Korea


or

Nicole Pratt, PhD, Associate Professor

Quality Use of Medicines and Pharmacy Research Centre
School of Pharmacy and Medical Sciences
University of South Australia
Adelaide, South Australia, Australia
Email: [email protected]

Log in for Subscribers

Citation